Article
Onset of valganciclovir resistance in two infants with congenital cytomegalovirus infection.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 1 Sept 2020
Garofoli Francesca, Lombardi Giuseppina, Angelini Micol, Campanini Giulia, Zavattoni Maurizio, Baldanti Fausto
Abstract excerpt
Ganciclovir and its prodrug valganciclovir are elective treatments for cCMV. Neonates with important symptoms undergo 6 months of therapy to ameliorate/prevent symptoms and late sequelae, but evidence of resistance is emerging. Over the last 5 years, we took care of 59 cCMV infants and experienced two cases of resistance among nine cCMV infants receiving long-term valganciclovir therapy. In the first case,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
